PURPOSE OF REVIEW: Kidney transplantation has improved the life expectancy and quality of life for patients with end-stage renal failure. However, despite the impressive improvements in short-term outcome parameters because of better and more potent immunosuppressive drugs, the long-term survival of renal allografts has changed little over the last decades. Sustained inflammation in the areas of interstitial fibrosis and tubular atrophy (IFTA) is a strong predictor of allograft failure. Mesenchymal stromal cells (MSCs) have potent anti-inflammatory and reparative properties, and could thus play a role in controlling these processes. RECENT FINDINGS: Local resident MSCs and exogenous MSCs have been implicated in the repair of the injured kidney, mostly by their paracrine functions. In the experimental models and clinical trials, first results with MSCs for the treatment of inflammation and IFTA suggest beneficial effects. SUMMARY: Endogenously and exogenously administered MSCs might enhance the intrinsic reparative capabilities of the kidney in transplant recipients and maybe developed as a tool to control both inflammation and fibrosis.
PURPOSE OF REVIEW: Kidney transplantation has improved the life expectancy and quality of life for patients with end-stage renal failure. However, despite the impressive improvements in short-term outcome parameters because of better and more potent immunosuppressive drugs, the long-term survival of renal allografts has changed little over the last decades. Sustained inflammation in the areas of interstitial fibrosis and tubular atrophy (IFTA) is a strong predictor of allograft failure. Mesenchymal stromal cells (MSCs) have potent anti-inflammatory and reparative properties, and could thus play a role in controlling these processes. RECENT FINDINGS: Local resident MSCs and exogenous MSCs have been implicated in the repair of the injured kidney, mostly by their paracrine functions. In the experimental models and clinical trials, first results with MSCs for the treatment of inflammation and IFTA suggest beneficial effects. SUMMARY: Endogenously and exogenously administered MSCs might enhance the intrinsic reparative capabilities of the kidney in transplant recipients and maybe developed as a tool to control both inflammation and fibrosis.
Authors: Cindy C Shu; Andrew Dart; Robin Bell; Christina Dart; Elizabeth Clarke; Margaret M Smith; Christopher B Little; James Melrose Journal: JOR Spine Date: 2018-10-10
Authors: Geertje J Dreyer; Koen E Groeneweg; Sebastiaan Heidt; Dave L Roelen; Melissa van Pel; Helene Roelofs; Volkert A L Huurman; Ingeborg M Bajema; Dirk Jan A R Moes; Willem E Fibbe; Frans H J Claas; Cees van Kooten; Rabelink J Rabelink; Johan W de Fijter; Marlies E J Reinders Journal: Am J Transplant Date: 2020-05-06 Impact factor: 8.086
Authors: Marlies E J Reinders; Geertje J Dreyer; Jonna R Bank; Helene Roelofs; Sebastiaan Heidt; Dave L Roelen; Maarten L Zandvliet; Volkert A L Huurman; Wim E Fibbe; Cees van Kooten; Frans H J Claas; Ton J Rabelink; Johan W de Fijter Journal: J Transl Med Date: 2015-11-04 Impact factor: 5.531
Authors: Maria Jose Ramirez-Bajo; Jordi Rovira; Marta Lazo-Rodriguez; Elisenda Banon-Maneus; Valeria Tubita; Daniel Moya-Rull; Natalia Hierro-Garcia; Pedro Ventura-Aguiar; Federico Oppenheimer; Josep M Campistol; Fritz Diekmann Journal: Front Cell Dev Biol Date: 2020-01-29